Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura

Current Opinion in Pediatrics

Volumn 20, Issue 1, 2008, Pages 8-16

  Kalpatthi, Ram ^a   Bussel, James B ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autoimmunity; Chemotherapy; Hemorrhage; Immunosuppression; Platelets

Indexed keywords

AKR 501; ALEMTUZUMAB; ALPHA INTERFERON; AMINOCAPROIC ACID; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; DEXAMETHASONE; DOXORUBICIN; ELTROMBOPAG; ETANERCEPT; HEMOSTATIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; REMIPLISTIM; RHESUS D ANTIBODY; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; B LYMPHOCYTE; BEDTIME DOSAGE; BLEEDING; CHILL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG FEVER; ERADICATION THERAPY; FAMILY; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLAMMATION; LOW DRUG DOSE; MEGAKARYOPOIESIS; NEPHROTOXICITY; NEUTROPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTOPOIESIS; TOXICITY; TREATMENT PLANNING; URTICARIA;

CHILD; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 38149134581     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f45bb9     Document Type: Review

References (70)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
3. Di Paola JA, Buchanan GR. Immune thrombocytopenic purpura. Pediatr Clin North Am 2002; 49:911-928.
4. Dickerhoff R, Von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000; 137:629-632.
5. Imbach P, Akatsuka J, Blanchette V, et al. Immunothrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 1995; 154:S60-S64.
6. Buchanan GR, Journeycake JM, Adix L. Severe chronic idiopathic thrombocytopenic purpura during childhood: definition, management, and prognosis. Semin Thromb Hemost 2003; 29:595-603.
7. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006; 4:1664-1672.
8. Vianelli N, Galli M, De Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90:72-77.
9. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost 2003; 29:605-617.
10. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133:364-374. This review describes and discusses the pathophysiology of ITP in great detail, and provides a wider range of references than is available here.
11. Zhou B, Zhao H, Yang RC, Han ZC. Multidysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 2005; 54:107-116.
12. Berchtold P, McMillan R, Tani P, et al. Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura. Blood 1989; 74:1600-1602.
13. Tani P, Berchtold P, McMillan R. Autoantibodies in chronic ITP. Blut 1989; 59:44-46.
14. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006; 108:943-946. This paper provided experimental evidence that specificity of antiplatelet antibodies will determine response to IVIG did not ameliorate ITP in mice with anti-GPIb/IX antibodies because antibodies to platelet glycoprotein IB/IX destroy platelets by Fc receptor-independent means.
15. •] in ITP patients. It is important because if we could better predict response to IVIG this would be very helpful.
16. Nishioka T, Yamane T, Takubo T, et al. Detection of various platelet-associated immunoglobulins by flow cytometry in idiopathic thrombocytopenic purpura. Cytometry B Clin Cytom 2005; 68:37-42.
17. Hed J. Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl 1998; 424:37-40.
18. Semple JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura. Transfus Apher Sci 2003; 28:237-242.
19. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87:4245-4254.
20. h2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002; 100:1774-1779.
21. h1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007; Epub ahead of print.
22. Chang-Lin WU, Jian-Cheng XU, Fang LI, et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura. Int J Lab Hematol 2007; 29:177-184.
23. + regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78:139-143.
24. Psaila B, Bussel JB. Insights into therapeutic mechanisms: measuring immature platelet fraction (IPF) describes response to treatment in immune thrombocytopenic purpura (ITP) [abstract]. Blood 2006; 108:319a.
25. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003; 17:69-80.
26. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38:1-10.
27. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Am Physicians 1965; 78:374-390.
28. Branehog I, Kutti J, Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1974; 27:127-143.
29. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523-539.
30. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 1985; 65:584-588.
31. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40.
32. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989; 320:974-980.
33. Siegel RS, Rae JL, Barth S, et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989; 30:206-212.
34. Houwerzijl EJ, Blom NR, Van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103:500-506.
35. Ucar C, Oren H, Irken G, et al. Investigation of megakaryocyte apoptosis in children with acute and chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70:347-352.
36. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005; 81:94-99.
37. Gu J, Lu L, Xu R, Chen X. Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl) 2002; 115:983-986.
38. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728-730.
39. Rice L, Nichol JL, McMillan R, et al. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68:210-214.
40. Michel M, Kreidel F, Chapman ES, et al. Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica 2005; 90:1715-1716.
41. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 1988; 72:121-127.
42. Imbach P, Barandun S, Hirt A, Wagner HP. Intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) in childhood. Am J Pediatr Hematol Oncol 1984; 6:171-174.
43. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146:217-221.
44. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639-2642.
45. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106:2244-2251.
46. Food and Drug Administration. Rituxan warning. FDA Consum 2007; 41:3.
47. Franchini M, Veneri D. Helicobacter pylori infection and immune thrombocytopenic purpura: an update. Helicobacter 2004; 9:342-346.
48. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004; 124:91-96.
49. Jaing TH, Yang CP, Hung IJ, et al. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003; 92:1153-1157.
50. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364-1369.
51. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102:887-895.
52. Aledort LM, Hayward CP, Chen MG, et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205-213.
53. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457-3469.
54. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
55. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681.
56. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; Epub ahead of print.
57. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101:71-77.
58. Wrobel G, Dobaczewski G, Patkowski D, et al. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006; 47:729-730.
59. Monroe DM, Hoffman M, Allen GA, Roberts HR. The Factor VII-platelet interplay: effectiveness of recombinant Factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26:373-377.
60. Aguilar C, Lucia JF. Successful control of severe postoperative bleeding with recombinant Factor VIIa in a case of refractory idiopathic thrombocytopenic purpura. Am J Hematol 2007; 82:246-247.
61. Imbach P. Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options. Paediatr Drugs 2003; 5:795-801.
62. Perrotta S, Amendola G, Locatelli F, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003; 121:143-147.
63. Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP. Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999; 21:77-79.
64. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81:19-25.
65. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70:353-357.
66. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330:1560-1564.
67. Meeker ND, Goldsby R, Terrill KR, et al. Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25:173-175.
68. McMinn JR Jr, Cohen S, Moore J, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 2003; 73:135-140.
69. Hrstkova H, Bajer M, Michalek J. Recombinant human interferon alpha-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2002; 24:299-303.
70. Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001; 3:189-195.